An Open Label Phase 2 Study to Evaluate PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma

Trial Profile

An Open Label Phase 2 Study to Evaluate PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 May 2017

At a glance

  • Drugs PT 2385 (Primary)
  • Indications Renal cell carcinoma; Von Hippel-Lindau disease
  • Focus Therapeutic Use
  • Sponsors Peloton Therapeutics
  • Most Recent Events

    • 11 May 2017 According to a Peloton Therapeutics media release, patient dosing has been initiated in this trial.
    • 25 Apr 2017 Status changed from not yet recruiting to recruiting.
    • 13 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top